530 related articles for article (PubMed ID: 16267007)
21. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells.
Munchhof AM; Li F; White HA; Mead LE; Krier TR; Fenoglio A; Li X; Yuan J; Yang FC; Ingram DA
Hum Mol Genet; 2006 Jun; 15(11):1858-69. PubMed ID: 16648142
[TBL] [Abstract][Full Text] [Related]
22. The C. elegans methionine aminopeptidase 2 analog map-2 is required for germ cell proliferation.
Boxem M; Tsai CW; Zhang Y; Saito RM; Liu JO
FEBS Lett; 2004 Oct; 576(1-2):245-50. PubMed ID: 15474045
[TBL] [Abstract][Full Text] [Related]
23. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes.
Kim HA; Rosenbaum T; Marchionni MA; Ratner N; DeClue JE
Oncogene; 1995 Jul; 11(2):325-35. PubMed ID: 7624147
[TBL] [Abstract][Full Text] [Related]
24. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.
Costa RM; Federov NB; Kogan JH; Murphy GG; Stern J; Ohno M; Kucherlapati R; Jacks T; Silva AJ
Nature; 2002 Jan; 415(6871):526-30. PubMed ID: 11793011
[TBL] [Abstract][Full Text] [Related]
25. Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice.
Wu M; Wallace MR; Muir D
J Neurosci Res; 2005 Nov; 82(3):357-67. PubMed ID: 16180234
[TBL] [Abstract][Full Text] [Related]
26. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.
Xu J; Ismat FA; Wang T; Yang J; Epstein JA
Circulation; 2007 Nov; 116(19):2148-56. PubMed ID: 17967772
[TBL] [Abstract][Full Text] [Related]
27. Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells.
Thomas SL; Deadwyler GD; Tang J; Stubbs EB; Muir D; Hiatt KK; Clapp DW; De Vries GH
Biochem Biophys Res Commun; 2006 Sep; 348(3):971-80. PubMed ID: 16908010
[TBL] [Abstract][Full Text] [Related]
28. p67/MetAP2 suppresses K-RasV12-mediated transformation of NIH3T3 mouse fibroblasts in culture and in athymic mice.
Majumdar A; Ghosh A; Datta S; Prudner BC; Datta B
Biochemistry; 2010 Nov; 49(47):10146-57. PubMed ID: 21033716
[TBL] [Abstract][Full Text] [Related]
29. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
30. Discovery, identification, and characterization of candidate pharmacodynamic markers of methionine aminopeptidase-2 inhibition.
Warder SE; Tucker LA; McLoughlin SM; Strelitzer TJ; Meuth JL; Zhang Q; Sheppard GS; Richardson PL; Lesniewski R; Davidsen SK; Bell RL; Rogers JC; Wang J
J Proteome Res; 2008 Nov; 7(11):4807-20. PubMed ID: 18828628
[TBL] [Abstract][Full Text] [Related]
31. Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases.
Datta B; Majumdar A; Datta R; Balusu R
Biochemistry; 2004 Nov; 43(46):14821-31. PubMed ID: 15544353
[TBL] [Abstract][Full Text] [Related]
32. Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo.
Huang ZY; Baldwin RL; Hedrick NM; Gutmann DH
Oncogene; 2002 Feb; 21(9):1325-34. PubMed ID: 11857076
[TBL] [Abstract][Full Text] [Related]
33. Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation.
Tucker LA; Zhang Q; Sheppard GS; Lou P; Jiang F; McKeegan E; Lesniewski R; Davidsen SK; Bell RL; Wang J
Oncogene; 2008 Jun; 27(28):3967-76. PubMed ID: 18264137
[TBL] [Abstract][Full Text] [Related]
34. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
35. Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.
Lu J; Chong CR; Hu X; Liu JO
J Med Chem; 2006 Sep; 49(19):5645-8. PubMed ID: 16970390
[TBL] [Abstract][Full Text] [Related]
36. Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis.
Zhou G; Tsai CW; Liu JO
J Med Chem; 2003 Jul; 46(16):3452-4. PubMed ID: 12877582
[TBL] [Abstract][Full Text] [Related]
37. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
[TBL] [Abstract][Full Text] [Related]
38. NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos.
Kuorilehto T; Nissinen M; Koivunen J; Benson MD; Peltonen J
J Bone Miner Res; 2004 Jun; 19(6):983-9. PubMed ID: 15125795
[TBL] [Abstract][Full Text] [Related]
39. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.
Banerjee S; Crouse NR; Emnett RJ; Gianino SM; Gutmann DH
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15996-6001. PubMed ID: 21896734
[TBL] [Abstract][Full Text] [Related]
40. Molecular genetic analyses in neurofibromatosis type 1 patients with tumors.
Oguzkan S; Terzi YK; Cinbis M; Anlar B; Aysun S; Ayter S
Cancer Genet Cytogenet; 2006 Mar; 165(2):167-71. PubMed ID: 16527612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
